Search Results for "sunscreens"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for sunscreens. Results 21 to 28 of 28 total matches.

Tazarotene (Tazorac) for Acne

   
The Medical Letter on Drugs and Therapeutics • Jun 10, 2002  (Issue 1132)
and use sunscreens. Even though systemic absorption is minimal, the drug is contraindicated in pregnancy ...
Tazarotene (taz ar' oh teen, Tazorac - Allergan), an acetylinic retinoid marketed for treatment of psoriasis (Medical Letter 1997; 39:105), is also available as a 0.1% gel and cream for treatment of acne.
Med Lett Drugs Ther. 2002 Jun 10;44(1132):52-3 |  Show IntroductionHide Introduction

Hydrogen Peroxide 40% (Eskata) for Seborrheic Keratoses

   
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018  (Issue 1556)
, and topical products such as makeup or sunscreen should not be used for at least 6 hours. After 3 weeks ...
The FDA has approved hydrogen peroxide 40% topical solution (Eskata – Aclaris Therapeutics) for treatment of raised seborrheic keratoses (SKs) in adults. It is the first drug to be approved for this indication. (Hydrogen peroxide is available over the counter for topical use as a 3% solution.)
Med Lett Drugs Ther. 2018 Sep 24;60(1556):157-8 |  Show IntroductionHide Introduction

Dermal Fillers

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
) for Breast Cancer Sunscreens Coming Soon in Treatment Guidelines: Choice of Antibacterial Drugs – May 2007 ...
Several injectable products are available for soft tissue augmentation of wrinkles and folds. These fillers are often used in conjunction with botulinum toxin type A (Botox) injections.
Med Lett Drugs Ther. 2007 May 7;49(1260):39-40 |  Show IntroductionHide Introduction

Sparfloxacin and Levofloxacin

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 1997  (Issue 999)
, including some who used sunscreens; the manufacturer advises cautioning patients to avoid direct ...
Sparfloxacin (Zagam - Rh ne-Poulenc Rorer) and levofloxacin (Levaquin - Ortho-McNeil) are the newest fluoroquinolone antimicrobials to be approved by the US Food and Drug Administration. Sparfloxacin in a once-daily oral preparation is being marketed for treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. Levofloxacin, which is the active stereoisomer of ofloxacin (Floxin), is available for either oral or parenteral use; it is approved for oncedaily treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis,...
Med Lett Drugs Ther. 1997 Apr 25;39(999):41-3 |  Show IntroductionHide Introduction

Voclosporin (Lupkynis) for Lupus Nephritis

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
should limit or avoid sun exposure and artificial UV light and use sunscreen with a high sun protection ...
Voclosporin (Lupkynis – Aurinia), an oral calcineurin inhibitor, has been approved by the FDA for use in combination with the antimetabolite immunosuppressant mycophenolate mofetil (Cellcept, and generics) and a corticosteroid for treatment of adults with active lupus nephritis. It is the first calcineurin inhibitor to be approved in the US for this indication. Tacrolimus (Prograf, and others) and cyclosporine (Neoral, and others), the other available systemic calcineurin inhibitors, are approved for prophylaxis of organ rejection in transplant patients.
Med Lett Drugs Ther. 2021 Aug 23;63(1631):134-6 |  Show IntroductionHide Introduction

Panitumumab (Vectibix) for Metastatic Colorectal Cancer

   
The Medical Letter on Drugs and Therapeutics • Apr 23, 2007  (Issue 1259)
Cancer Sunscreens Coming Soon in Treatment Guidelines: Choice of Antibacterial Drugs – May 2007 Drugs ...
Panitumumab (Vectibix - Amgen), a fully human IgG2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of patients with EGFR-expressing metastatic colorectal cancer that has progressed despite standard chemotherapy. It is the second monoclonal antibody EGFR inhibitor to be approved for metastatic colorectal cancer; cetuximab (Erbitux), a human-murine chimeric IgG1 monoclonal antibody, was approved in 2004.
Med Lett Drugs Ther. 2007 Apr 23;49(1259):35-6 |  Show IntroductionHide Introduction

Adapalene-Benzoyl Peroxide (Epiduo) for Acne

   
The Medical Letter on Drugs and Therapeutics • Apr 20, 2009  (Issue 1310)
exposure to sunlight, use sunscreen and wear protective clothing. CONCLUSION — Adapalene 0.1%-benzoyl ...
Epiduo gel (Galderma), a fixed-dose combination of adapalene 0.1% (Differin), a synthetic retinoid analog, and benzoyl peroxide (BPO) 2.5%, an oxidizing agent, has been approved by the FDA for topical treatment of acne vulgaris in patients ≥12 years old.
Med Lett Drugs Ther. 2009 Apr 20;51(1310):31-2 |  Show IntroductionHide Introduction

Erythropoietin Safety Concerns

   
The Medical Letter on Drugs and Therapeutics • May 07, 2007  (Issue 1260)
Lapatinib (Tykerb) for Breast Cancer Sunscreens Coming Soon in Treatment Guidelines: Choice ...
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
Med Lett Drugs Ther. 2007 May 7;49(1260):37-9 |  Show IntroductionHide Introduction